Pfizer Inc and Bioren Inc have completed a transaction in which Pfizer purchased all outstanding stock of Bioren for an undisclosed amount. Bioren is a California-based, privately held company specializing in technology for optimizing antibodies.
Antibody optimization technologies assist drug companies in developing medicines with improved properties such as greater and longer lasting efficacy. Bioren has developed Walk-Through Mutagenesis (WTM) and Look-Through Mutagenesis (LTM) technologies to improve the drug development of antibodies.
"The acquisition of Bioren strengthens Pfizer's commitment to the antibody space," Nick Saccomano, Pfizer’s senior vice president for Worldwide Research Technology said adding, “The ability to use and develop these technologies will help Pfizer identify new antibody leads as well as improve current antibodies in development."